Study of GT729 Cell Injection for Treating Refractory or Relapsed Chronic Graft-versus-Host Disease cGVHD in Adults Aged 18 to 65

What this Trial Is About

Researchers are evaluating the safety and effectiveness of GT729 universal cell injection for treating patients with refractory or relapsed chronic graft-versus-host disease cGVHD following allogeneic hematopoietic stem cell transplantation. This early phase 1 clinical trial aims to understand how this biological treatment affects people who have not responded to at least two prior systemic therapies for active cGVHD. Participants will receive the GT729 injection as the experimental treatment. The study will monitor participants from the time of infusion through 24 months to assess safety outcomes such as dose limiting toxicity within 28 days and the occurrence of adverse events. Researchers will also evaluate the overall response rate up to 6 months after the infusion. During the study, participants will undergo regular assessments including laboratory tests to monitor blood counts, liver and kidney function, and pregnancy status for women of childbearing age. Safety and treatment response will be closely observed throughout the treatment period. The total participation duration may last up to two years for long-term safety monitoring and outcome evaluation.

A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)